Podcasts about new drugs

Dr. William Li, physician, scientist, and president of the Angiogenesis Foundation, joins the show to explain how circulation, the gut microbiome, and inflammation shape our risk of heart disease, cancer, and brain disorders. In this conversation, he breaks down surprising discoveries about microplastics, GLP-1 weight-loss drugs, stem cells, and why the health of our blood vessels may be the hidden key to longevity. Dr. Li is also the author of the bestselling book Eat to Beat Disease, where he explores how food can activate the body's natural defense systems.In our conversation we discuss:(0:00) Introduction(1:32) Why Most People Die From Heart, Brain, or Cancer(1:54) The Real Common Denominator: Circulation(2:18) Why Blood Vessels Control Health(2:44) Young People Getting Diseases of Aging(3:24) Why Researchers Are Looking for the “Smoking Gun”(4:34) Chronic Inflammation Explained(6:04) Environmental Causes of Inflammation(8:19) Microplastics From Car Tires(9:15) Pollution, Water Contamination, and Toxins(11:09) Gut Microbiome: Your 39 Trillion Bacteria(12:15) How Gut Bacteria Control Brain, Mood, and Metabolism(13:24) The Firefighter Role of Good Bacteria(14:44) Dysbiosis and Chronic Disease(15:54) The Gut–Brain Connection(16:32) Is the Appendix Actually Important?(18:11) Why Longevity Studies Take Decades(21:24) Anti-Inflammation Insights From Drug Studies(23:40) GLP-1 Drugs and the Weight Loss Revolution(25:15) Why GLP-1 May Protect the Heart(27:18) Should Healthy People Take GLP-1 For Longevity?(29:40) Side Effects of GLP-1 Medications(32:12) The Unknown Long-Term Effects of New Drugs(34:05) Why Longevity Research Is So Hard(36:30) Stem Cells Explained (Stem Cells 101)(39:17) The 70 Million Stem Cells You're Born With(41:24) Why Stem Cells Decline With Age(43:21) The Truth About Stem Cell Clinics(46:14) Foods That Can Mobilize Your Stem Cells(48:42) Microplastics: Easy Ways to Reduce Exposure(53:08) Water Filters and Reverse Osmosis Debate(56:03) Air Quality and Why It Matters For Health(59:03) Meal Timing, Fasting, and Energy(1:02:24) Why Not Eating Can Improve Health(1:05:42) What To Eat For Breakfast(1:09:42) The Future of Personalized Nutrition(1:13:25) Measuring Your Microbiome(1:17:52) The Next Frontier of Health Research(1:20:54) Food Potency and Superfoods(1:24:23) Longevity vs Quality of Life(1:28:09) The Philosophy of Healthy Aging(1:30:48) Where to Follow Dr. William LiLearn more about Dr. William Li here:Website: https://drwilliamli.com/Youtube: https://www.youtube.com/@DrWilliamLiListen to the full episode here:https://youtu.be/Z20c9JqkbTw

WSJM Afternoon News for 03-02-26See omnystudio.com/listener for privacy information.

WSJM Afternoon News for 03-02-26See omnystudio.com/listener for privacy information.

Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USOne on One Video Call W/George https://tidycal.com/georgepmonty/60-minute-meetingPSYCHEDELIC COMPOUNDSThat No One Has Made But I Think I Would LoveEpisode Six: THALASSINE-7(7-OH-Mitragynine-DMT Conjugate / Sigma-2 Agonist / Cortistatin Analog)“The compound that puts you in the water. The water that is already in you.”✦Episode SummaryThis episode delivers a haunting, second-person narrative of THALASSINE-7, a purely theoretical psychedelic that doesn't flood you with new visions — it turns up the volume on what your body is already screaming, clears the static of self-protection, and holds you in crystal-clear confrontation with the self at depth.Framed through a father and his nine-year-old daughter's real-time fight against a rip current at Three Tables Beach on Oahu's North Shore, the “trip” becomes an unflinching mirror for overconfidence, the weight of trust, ignoring warning signs, and the difference between survival and wisdom.The Compound (Theoretical Pharmacology)•  Backbone: Modified 7-hydroxymitragynine redirected from opioid receptors to sigma-2 agonism (mitochondrial receptors that govern the cellular “continue or quit” decision — literally apoptosis/survival signaling).•  Psychedelic Link: 5-substituted DMT moiety connected via sulfonyl linker, creating allosteric cross-talk that amplifies whatever signal your nervous system is already broadcasting instead of overlaying new hallucinations.•  Rest Component: Cortistatin-14 analog — the same neuropeptide your brain releases in deep slow-wave sleep — brought into full waking consciousness to quiet hippocampal chatter and deliver profound, low-static rest while you remain completely alert.Net Effect: Complete wakefulness + total removal of narrative armor + inescapable bodily truth = an encounter with reality you cannot file away.Status: 100% theoretical / fever-dream medicinal chemistry. No one has synthesized this. The lessons it forces are very real.The Trip Report: Three Tables Beach, Pupukea, North Shore OahuSetting: Overcast grey morning at the beach named for three flat coral reef tables visible at low tide. Multiple posted signs warn of powerful rip currents, hazardous shorebreak, and past deaths. The father enters the water anyway with his trusting daughter on his back.Key Moments (clinical timestamps from the narrative):•  T+0:00 — Reading the signs… and walking in.•  T+0:22 — The current slams. Sigma-2 receptors light up with the body's primal “continue” verdict.•  T+0:25–0:41 — Arm-over-arm fight; daughter silent, gripping, sixty-two pounds feeling like the entire world.•  T+0:58 — Shore reached. Arms shaking in six inches of water. Pride and reckoning land simultaneously.•  T+1:20 — The compound forces both truths at once: I brought her back and I never should have taken her in.•  T+2:00 — Integration on the sand: You are not the exception. Do the work in calm water before the current changes again.Real Location NoteThree Tables Beach (also called Kalua o Māua) is a real spot between Waimea Bay and Sharks Cove. It offers world-class snorkeling in summer but is notorious for sudden, powerful rip currents and rogue waves, especially October–April. Signs explicitly warn “Deaths have occurred,” “Strong rip currents capable of pulling swimmers far out to sea,” and “Enter at your own risk.” Recent incidents include drownings and rescues. There is no permanent lifeguard tower. Always check conditions and heed every sign.Core Themes & Takeaways•  The universal “gap at the sign” — the split-second where information becomes discomfort and we quietly decide “that doesn't apply to me.”•  Holding both pride in what your body refused to quit and accountability for the unnecessary risk.•  The ocean as the cleanest laboratory: it applies the same physics to everyone regardless of how much you love the person beside you or how strong your story says you are.•  Capacities are not equal — this is physics, not morality. The ethical response is ruthless honesty about where you actually are and deliberate work to close the gap.•  Parenting in action: what you model when the signs are clear echoes louder than any lecture.•  “Go do the work. In calm water. Before the current changes again.”Key Quote“You are not the exception. You are a person who, when the situation became the thing it was always warning you it might become, found out what you are actually made of. And what you are made of was enough. This time.”Synthesist's NotesThe specific conjugate (sulfonyl-linked 7-OH-mitragynine-DMT-cortistatin analog) exists only in speculation, but every piece draws from documented science: sigma-2 receptors in mitochondria, cortistatin's role in deep sleep consolidation, and the well-known potency of 7-hydroxymitragynine. What is not speculative is the psychological target — the moment we read a warning and override it with self-flattery. THALASSINE-7 is the compound that refuses to let you file that discomfort under “confidence” and keeps the gap open until it becomes transformation.Next EpisodeCHRONOGEN — a peptide-psychedelic hybrid that does not alter time perception. It alters time preference. The body begins to want the present with such ferocity that past and future lose their gravitational pull. The calendar has been keeping records of every appointment your future self never received. It is not angry. It is just waiting.✦END OF EPISODE SIXTHALASSINE-7 • Status: Theoretical. The signs were always right.Thank you for listening (or reading). If this episode moved you, sit with the gap at your own signs today. The water is already in you. One on One Video call W/George https://tidycal.com/georgepmonty/60-minute-meetingSupport the show:https://www.paypal.me/Truelifepodcast?locale.x=en_US

Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USOne on One Video Call W/George https://tidycal.com/georgepmonty/60-minute-meetingThe metal detector isn't checking whether the building is dangerous for you…it's checking if you are dangerous for those inside! Episode Five of Psychedelic Compounds That No One Has Made But I Think I Would Love. DIGNIN: a peptide-tryptamine hybrid that temporarily takes the cortisol offline and asks it, at the molecular level, whether the threat is real or just a habit. Spoiler: it's a habit. You built it. You've been maintaining it for years. You're very good at it. This is the compound that shows you the blueprints. One on One Video call W/George https://tidycal.com/georgepmonty/60-minute-meetingSupport the show:https://www.paypal.me/Truelifepodcast?locale.x=en_US

Listen without ads at www.patreon.com/dopeypodcastToday on Dopey!  We promote Dopeywood 2026 tickets (April 12 at Comedy Store LA with Marc Maron, Bobby Lee, Margaret Cho, Darrell Hammond, Sam Miller, Allie Makovsky, Zach Noe Towers.Tickets For Dopeywood 2026: https://www.showclix.com/event/dopeywood-2026Also if you want free Narcan/fentanyl test strips write us at dopeypodcast@gmail.com  We Read glowing Spotify feedback on the "Yellow Balloon" episode (jam band recovery groups like Much Obliged), including shoutouts to Benji, hippie Earl's gratitude lists/Secret Santa, and defends five-days-a-week Dopey. Shares Dana's email/story: Philly trank/xylazine struggles, listening while using (sad/lonely but less alone), hilarious failed gas station robberies with an oxy coworker (no masks/weapons, polite denials, eventual $300 haul for pills/McDonald's). Then dives into a marathon convo with Bob Forrest (Don't Die podcast, Celebrity Rehab, Thelonious Monster): Bob's anti-device/oligarch rant (Elon Musk/Jeff Bezos/curated feeds as modern Matrix, Bob Marley money quote, fight fake reality, turn off phones, go outside), social media dividing people (Gaza/Pizzagate/Epstein conspiracies as distractions from economic rape), drug market shifts (meth in fentanyl to preserve customers post-Narcan, cocaine resurgence over crazy-making meth, Kratom ubiquity as "non-addictive" supplement denial), modern addicts numbing vs. old-school enhancement, generational hopelessness (kids glued to iPads, no humor/alive feeling), AA tough love vs. today's softness, economic insecurity fearlessness in recovery, personal racism persistence, unity/civility over war, and life's joy in helping addicts. Ends with Mike Martt/Nick Thorpe's "Good So Bad" cover!SEO Search Terms: Suggested Title: Today on Dopey! Wednesday Dose: Bob Forrest Rants Oligarchs/Social Media Matrix, Fentanyl Meth Shifts, Unity Over Division + Nora's Sweet Sober Dad Moment (Valentine's 2026) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dinesh Patel, PhD, CEO of Protagonist Therapeutics, discusses the New Drug Application (NDA) submission to the US Food and Drug Administration (FDA) for rusfertide to treat adults with polycythemia vera (PV).PV is characterized by excess red blood cells in the bloodstream, increasing the risk for blood clots. Most cases of PV are acquired and occur more frequently in men than in women. The condition has been associated with genetic changes in the JAK2 and TET2 genes. Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV.The NDA submission is based on positive 32-week primary analysis and 52-week results from the phase 3, global, randomized, placebo-controlled VERIFY clinical trial (NCT05210790). In this study, patients receiving rusfertide plus standard of care therapy demonstrated a substantially higher response rate compared to placebo plus standard of care, including durable hematocrit control, a reduction in phlebotomy requirements and improvement in pre-specified patient reported outcome endpoints.Rusfertide has received Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation from the FDA.

Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USOne on One Video Call W/George https://tidycal.com/georgepmonty/60-minute-meeting═══════════════════════════════════════════════════════════════════PSYCHEDELIC COMPOUNDS THAT NO ONE HAS MADE BUT I THINK I WOULD LOVE═══════════════════════════════════════════════════════════════════EPISODE 02: Ψ-COLLAPSE(3,4-Methylenedioxy-N-Superposition-Amphetamine)"The compound that makes you all possible versions of yourself at once, then forces you to choose which one survives measurement."═══════════════════════════════════════════════════════════════════

The Hidden Lightness with Jimmy Hinton – For years, Americans have paid the highest drug prices on the planet—sometimes more than 1,000 percent higher than what patients pay in other developed nations for the exact same medications. TrumpRx.gov represents an aggressive attempt to bring transparency and accountability to a system long dominated by pharmaceutical giants...

Today, we're diving into an increasingly urgent and complex area of frontline medicine: novel psychoactive substances and synthetic drugs. Over the past decade, the drug landscape has shifted dramatically. Potent synthetics, unpredictable chemical variants, and rapidly evolving supply chains are creating new clinical challenges for ambulance crews, HEMS teams, and frontline responders. These substances don't play by traditional rules; presentations can be extreme, toxidromes atypical, and responses to treatment unpredictable. To help us understand this shifting landscape, I'm joined byDr Caroline Copeland, Senior Lecturer in Pharmacology and Toxicology at King's College London and Director of the National Programme on Substance Use Mortality. Caroline is one of the UK's leading experts in drug-related harms, combining pharmacology, epidemiology, and innovative data science to better understand emerging substances and their real-world impact. She advises national bodies, contributes to the ACMD's Novel Psychoactive Substances Committee, and leads national surveillance programmes shaping policy and practice. Today, she helps us unpack what clinicians need to know, what's changing, and how we can better protect patients in a rapidly evolving drug landscape. Caroline's work and publications can be found here: https://www.kcl.ac.uk/people/caroline-copelandThis episode is sponsored by PAX: The gold standard in emergency response bags.When you're working under pressure, your kit needs to be dependable, tough, and intuitive. That's exactly what you get with PAX. Every bag is handcrafted by expert tailors who understand the demands of pre-hospital care. From the high-tech, skin-friendly, and environmentally responsible materials to the cutting-edge welding process that reduces seams and makes cleaning easier, PAX puts performance first. They've partnered with 3M to perfect reflective surfaces for better visibility, and the bright grey interior makes finding gear fast and effortless, even in low light. With over 200 designs, PAX bags are made to suit your role, needs, and environment. And thanks to their modular system, many bags work seamlessly together, no matter the setup.PAX doesn't chase trends. Their designs stay consistent, so once you know one, you know them all. And if your bag ever takes a beating? Their in-house repair team will bring it back to life.PAX – built to perform, made to last.Learn more at ⁠https://www.pax-bags.com/en/⁠

AP's Lisa Dwyer reports on new negotiations on Medicare drug pricing.

In episode #97 of “The Weekly Bioanalysis” podcast, John and Dom focus on a review of 2025 drug approvals, revealing a surprisingly strong year for small molecules despite long-standing predictions of their decline. Of the 53 FDA approvals, 31 were small molecules, with additional complexity coming from ADCs and RNAi therapies, underscoring the continued importance of small-molecule development and analytics. The hosts also compare U.S. and European approvals, noting meaningful differences driven by regulatory timing and regional priorities rather than scientific divergence. They highlight encouraging momentum in ADCs, the role of acquisitions in successful approvals, and a broad mix of indications—from rare diseases and oncology to neurology and vaccines. Overall, the episode reinforces that innovation remains diverse, with small molecules, large molecules, and conjugated technologies all playing critical roles in modern drug development. If you want a comprehensive view of the noteworthy approvals from 2025, this is the episode you're looking for!“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.

Contributing writer Jake Fogleman and I break down last week's oral arguments in Wolford v. Lopez, which saw a majority of the Supreme Court justices express skepticism toward the legality of Hawaii's "Vampire Rule" gun carry law. We also talk about the ATF's new proposal to redefine who counts as an "unlawful drug user" for the purposes of federal gun law.

About this episode: Medetomidine, a veterinary sedative similar to xylazine, is appearing more frequently in drug supplies in Maryland, Delaware, and Pennsylvania—and the withdrawal symptoms are debilitating. In this episode: Addiction medicine specialist Jordan Nahas-Vigon details the risks facing people who use drugs and why it's so difficult to quit. Guests: Dr. Jordan Nahas-Vigon is a primary care doctor with Johns Hopkins Medicine who specializes in addiction medicine. Host: Dr. Josh Sharfstein is distinguished professor of the practice in Health Policy and Management, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: A Powerful New Drug Is Creating a 'Withdrawal Crisis' in Philadelphia—New York Times Why the animal sedative behind a Baltimore mass overdose is so hard to quit—The Baltimore Banner Sedative 'dex' is replacing 'tranq' in illegal drug supply and causing excruciating withdrawal—STAT The Xylazine Crisis—Public Health On Call (May 2023) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌PublicHealthPod on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Dr. Santina Wheat, Program Director, McGaw Northwestern Family Medicine Residency Northwestern Medicine, Delnor Hospital, joins Dean Richards for this week's health update. They talk about the development of a drug to combat Alzheimer’s and ALS and give an update on the super flu.

Send us a textIn this episode of Cannabis Legalization News, host Tom updates viewers on the latest developments in federal cannabis policy, focusing on federal law, administrative choices, and the potential rescheduling of cannabis. The episode features a conversation with a new member, Joshua Potter, and a deep dive into consumer preferences for THC and CBD ratios in cannabis beverages. Tom also discusses the evolving landscape of legal cannabis in the U.S. and the international market's potential impact on legalization. Special guest Aaron Zeman joins from Hawaii to discuss his experiences with activism, legal battles, and the unique challenges of growing cannabis in Hawaii. The show concludes with a segment about the upcoming Hawaii Cannabis Expo and a fun 'Name That Strain' game featuring Relief Botanical's Humboldt Dream.00:00 Introduction and Weekly Overview00:26 Federal Law and Policy Changes01:12 Cannabis Beverage Market Discussion02:50 Rescheduling and Legalization Challenges12:59 Guest Interview: Activism and Legal Battles15:10 Supreme Court and Legal Precedents26:21 International Cannabis Market37:17 Compliance and Regulation in the Cannabis Industry40:58 Supreme Court and Firearms Case41:17 Legal Perspectives on Firearms and Cannabis42:07 Dormant Commerce Clause and Marijuana Commerce44:09 Regulatory Load in the Cannabis Industry46:16 Hawaii Cannabis Expo and Book Signing47:15 Challenges in the Cannabis Industry59:24 Cannabis Industry vs. Cannabis Plant01:02:07 Cannabis Legalization and Market Dynamics01:09:54 Hawaiian Cannabis Strains and Cultivation01:13:50 Closing Remarks and Future ProspectsSupport the showGet our newsletter: https://bit.ly/3VEn9vu

A Holiday tradition like few other. Are we keeping, regifting, or returning new oncology drugs approved in 2025?

Shimer teaches you the 6 scientific roots of your porn use, and gives you practical steps for eradicating them from your life for good. Ted Shimer has mentored men since 1991. He is a Dallas Seminary-trained Pastoral Sex Addiction Professional-Supervisor who helps people overcome the bondage of pornography in the context of making disciples.  Ted is the Founder of The Freedom Fight, an online porn addiction recovery program, and the author of the book, The Freedom Fight, The New Drug and the Truths that Set Us Free, which is our topic for today.  Jim's newest book, Guardrails: Ten Boundaries for an Unbreakable Marriage will be releasing in April 2026. Sign up to be notified when it's available at https://meninthearena.org/guardrails. This episode is sponsored by Compassion International. Our goal is for the Men in the Arena tribe to sponsor 1,000 boys over the coming year! Help us reach that goal and make a difference in a child's life today. When you sponsor a child using our link, you'll receive a free copy of Jim's book, Dialed In: Reaching Your Full Capacity as a Man of God! We are also sponsored by MTNTOUGH Fitness Lab, a Christian-owned fitness app. This app, combined with diet, has helped Jim get in the best shape of his life! Get 6 weeks free with the code ARENA30 at MTNTOUGH.com. Every man needs a locker room. Apply to join an exclusive brotherhood of like-minded men in The Locker Room, our monthly live Zoom Q&A call! We meet in the Locker Room once a month for community, fellowship, laughter, and to help each other find biblical answers to life's difficult questions. Locker Room members also get access to monthly exclusive leadership trainings, historically only available to the staff team at Men in the Arena. Membership is by application only. Go here to apply: https://patreon.com/themeninthearena Get Jim Ramos' USA TODAY Bestselling book, Dialed In: Reaching Your Full Capacity as a Man of God (https://tinyurl.com/dialedinbook)

Hour 3 of the Chris Hand Show | Wednesday 12-17-25See omnystudio.com/listener for privacy information.

A growing list of medications—such as zuranolone for postpartum depression, suzetrigine for pain, and the gepants class of migraine medicines—exist because of insights from basic research.

We are bringing you some actually good news and a new drug that is showing incredible promise in fighting HIV/AIDS. It's called lenacapavir. It's not available in Canada yet, but it's getting its first real-world test in three African countries. We talk to Dr Darrell Tan, a leading Canadian HIV prevention researcher about the promise of lenacapavir, and why Canadian doctors should be doing more to make sure HIV prevention drugs get to the people who need them most. And Dr Catherine Martin, a senior researcher with Wits Reproductive Health and HIV in Johannesburg.

Today, I want to warn you about a dangerous substance abuse trend which centers around an increasingly popular herbal drug which is available online and in stores, including gas stations and vape shops. Known as Kratom – K-r-a-t-o-m – the drug comes from the tree of the same name that is native to Southeast Asia. Users chew the tree's leaves, brew the leaves, or create a liquid extract. Users who ingest Kratom in low doses report that the effects are like those of a stimulant which increases alertness and energy. When used at higher doses, it works as a sedative to calm one's nerves and anxiety, and to reduce pain. The drug takes effect in minutes with the effects lasting a few hours. The physical side effects are many, and there also side effects on one's brain and nervous system, including hallucinations, and in some cases, death. Our kids are at risk, and we must warn them about the dangerous effects of this and all other drugs. Protect your kids by learning more about Kratom.

On today's episode, Vince sits down with Rob Dyer, former Marine and CIA paramilitary officer, to uncover a $10B gray-market plant product — a potent kratom derivative called 7-hydroxy (7-OH). This compound comes from the kratom leaf and is chemically enhanced to deliver a stronger, opioid-like effect. They break down the CCP's potential role, shadowy companies, and legal loopholes fueling this hidden industry few Americans know about. To purchase Borderland Merch, visit: https://thisisironclad.com/collections/borderland Borderland is an IRONCLAD Original 1stPhorm Go to⁠ ⁠https://www.1stphorm.com/borderland⁠⁠ and get free shipping on any orders over $75, free 30 days in the app for new customers, and 110% money back guarantee on all of our products. DeleteMe Go to https://www.joindeleteme.com/IRONCLAD and use coupon code IRONCLAD, or  scan the QR code TacPack  Visit http://www.TacPack.com  and use code IRONCLAD at checkout to get a free $70 tactical gift   AmmoSquared Visit https://ammosquared.com/ today for a special offer and keep yourself fully stocked. With over 100,000 members and thousands of 5-star ratings, Your readiness is their mission. Learn more about your ad choices. Visit megaphone.fm/adchoices

Joe Pags spotlights the explosive moment in Congress today as Nancy Mace publicly slams Rep. Corey Mills — and you'll understand exactly why he's now facing censure. Then, Rep. Brandon Gill steps up with a bold defense of America First, and Pags asks the obvious question: How is this even controversial in 2025? Finally — why is Ryan Wetting suddenly being labeled the “new drug lord”? Kash Patel and Pam Bondi break it all down, and Pags delivers the straight facts behind the headlines. A fast, fiery, can't-miss hour! Learn more about your ad choices. Visit megaphone.fm/adchoices

LISTEN and SUBSCRIBE on:Apple Podcasts: https://podcasts.apple.com/us/podcast/watchdog-on-wall-street-with-chris-markowski/id570687608 Spotify: https://open.spotify.com/show/2PtgPvJvqc2gkpGIkNMR5i WATCH and SUBSCRIBE on:https://www.youtube.com/@WatchdogOnWallstreet/featured  Cartel violence in Mexico just crossed another terrifying line — a mayor murdered, citizens storming government buildings, and a political climate where critics don't just get silenced… they get buried. With more than 30,000 cartel-related murders a year and American lives being devastated by fentanyl and synthetic opioids flowing across the border, patience is running thin.Now, reports say the Trump administration is quietly preparing potential U.S. special-operations plans inside Mexico — whether as real strategy or pressure tactics to force action from Mexico's government. But will Washington finally get serious about cartel power, or will corporate interests and political cowardice keep the status quo in place?Is this just a warning shot — or the first step toward a new front in the war on drugs?

Three Big Conversations: The new Frankenstein movie hits theaters. -  Deep-dive into the pornography-obsessed subculture known as "gooning,". - Why high-potency marijuana use is landing some users in the ER. -  Song of the Week - "The Fate of Ophelia" - Taylor Swift - Click here for the lyrics. -  Elsewhere in Culture: -  For the first time since 1990, there are no rap songs on the Billboard Top 40—marking the end of a 35-year streak. K-pop sensation BTS will end their three-year hiatus next year, embarking on a tour and releasing new music. A high school teacher went viral with a post on TikTok that showed the extreme way students reacted to his instruction to write a five-sentence paragraph.The as-yet-unidentified jewelry robbers who pulled off a heist at the Louvre were the topic of this week's social media fascination. YouTube is adding more content restrictions to better protect minors from encountering two types of content: online gambling and video games that depict graphic violence.  Check out our Ask Axis episode "How do I talk to my adult son about porn and screen addiction?" Check out Fight the New Drug for teens. Check out Pure Desire for adults. Become a monthly donor today, join the Table. For more Axis resources, go to axis.org.  

Tara unpacks an intense mix of political, economic, and public safety crises in this episode. She exposes alleged surveillance of the entire Republican ecosystem, explores Trump's global strategy to counter China's control over rare earth minerals, and breaks down the rising threat of synthetic opioids like xylazine and nidazines. Tara also examines financial markets, the U.S. economic landscape under tariffs, and controversial funding from organizations like the Gates Foundation tied to China's military. From domestic political battles to international negotiations, this episode covers the high-stakes conflicts shaping America today. Politics, power, and peril—what they're not telling you. Tara provides an exhaustive look at recent political and global developments, beginning with alleged massive surveillance targeting the Republican Party and its affiliates. She examines Trump's ongoing efforts to counter China's economic leverage on rare earth minerals and the deadly new synthetic opioids infiltrating the U.S. She also delves into financial news, including tariffs, inflation, and stock market trends, highlighting how economic manipulations affect everyday Americans. Tara further reveals connections between U.S. funding, the Gates Foundation, and China's military, emphasizing the critical stakes of global trade, public health, and political accountability. This episode blends investigative reporting with analysis of national security, public safety, and political strategy.

The new Frankenstein movie hits theaters, a deep-dive into the pornography-obsessed subculture known as "gooning," and why high-potency marijuana use is landing some users in the ER. Song of the Week - "The Fate of Ophelia" - Taylor Swift Click here for the lyrics. Elsewhere in Culture: For the first time since 1990, there are no rap songs on the Billboard Top 40—marking the end of a 35-year streak. K-pop sensation BTS will end their three-year hiatus next year, embarking on a tour and releasing new music. A high school teacher went viral with a post on TikTok that showed the extreme way students reacted to his instruction to write a five-sentence paragraph.The as-yet-unidentified jewelry robbers who pulled off a heist at the Louvre were the topic of this week's social media fascination. YouTube is adding more content restrictions to better protect minors from encountering two types of content: online gambling and video games that depict graphic violence. Check out our Ask Axis episode "How do I talk to my adult son about porn and screen addiction?" Check out Fight the New Drug for teens. Check out Pure Desire for adults. Become a monthly donor today, join the Table. For more Axis resources, go to axis.org.

America's hospitals will soon face an unprecedented rebate-based prescription drug model, come Jan. 1 – that's when there will be as many as 10 major drugs subject to Medicare price caps. This development is expected to create administrative and financial challenges for hospitals, which will have to pay the commercial price for such drugs while waiting for the rebates.For analysis and context, Maureen Testoni, president and CEO for 340B, will be the special guest during the next live edition of Monitor Monday. She will also review a recent Congressional Budget Office (CBO) report, featured in a recent Senate committee hearing, that includes some misrepresentations about why the 340B program has grown in recent years.As a special bonus, the longtime Internet broadcast produced by RACmonitor, will feature senior healthcare consultant Drew Updike, MD, who will recognize the tireless work being performed by the employees of the U.S. Department of Health and Human Services Office of Inspector General (HHS-OIG) who continue to work despite the federal shutdown, now in its fifth week.The weekly broadcast will also include these instantly recognizable features:Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.Legislative Update: Adam Brenman, senior legislative affairs analyst for Zelis, will report on the news happening at the intersection of healthcare and congressional action.

AI is everywhere these days, and though there's debate about how useful it is, one area where experts think it could be game-changing is scientific research. It promised to be particularly useful for speeding up drug discovery, an expensive and time-consuming process that can take decades. But so far, it hasn't panned out.The few AI-designed drugs that have made it to clinical trials haven't been approved, venture capital investment in these efforts has cratered in the last few years, and many startups have shut their doors. So why has it been so hard to make AI-designed drugs? What are the fundamental issues, and what does the future of this research look like?Joining Host Ira Flatow with some answers is Peter Coveney, who studies how chemistry discoveries can be sped up with algorithms and computers.Guest: Dr. Peter Coveney is a professor and director of the Centre for Computational Science at University College London.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

One of the things I'm seeing with the rise of GLP-1 weight loss drugs is other companies trying to use these drugs as a profit center. Today we'll look at a drug that is seeking approval to help those who take GLP-1s avoid some of the adverse events. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Stocks dropping across the board, as President Trump threatens a tariff increase on China. The sectors getting hit the hardest, and where government layoffs are beginning as the shutdown continues. Plus Another drug pricing deal in the pharma space. The company striking a deal with the President, and the reaction from the health care sector.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Endometriosis is estimated to affect one in ten Kiwi women, it can cause debilitating pain and really affect women's ability to live life to the fullest. But today we saw an exciting headline - the first treatment for endometriosis in nine years is now registered in New Zealand. It's called Ryeqo. Professor Neil Johnson, a gynaecologist from the Auckland Gynaecology Group, former president of the World Endometriosis Society, and an investigator for the international trials of Ryeqo chats to Jesse.

The U.S. government is now in its second week of a shutdown—with the FDA having paused acceptance of all new drug applications for the duration. But it was business as usual at the CDC, which adopted the recent recommendations of its newly revamped advisory committee on chickenpox and COVID-19 vaccines. And another senior leader, National Institute of Allergy and Infectious Diseases Director Jeanne Marrazzo, was fired last week, after filing a whistleblower report.  Across the country, cell and gene therapy leaders arrived in Phoenix for the annual Meeting on the Mesa, as the space remains in a state of flux—with regulatory and M&A momentum being stalled by commercial and market challenges. Takeda, for one, is looking to offload its cell therapy platform after years of hefty investment.  President Donald Trump's long-awaited tariffs did not hit on Oct. 1 as promised. But in the face of the looming levies, Pfizer signed a drug pricing deal with the White House that provides a three-year exemption. Amgen appears to be climbing onboard as well, announcing that its lipid-lowering drug Repatha will be available at a steep discount. These moves are all well and good for Big Pharma players, but a recent report from CRB reveals most smaller biopharma companies are not planning any investments to offset tariffs.  In our weekly weight loss segment, Skye Bioscience's cannabinoid receptor 1-targeting candidate nimacimab failed to outpace placebo in reducing body weight but elicited “intriguing synergy” in combination with Novo Nordisk's Wegovy, according to William Blair analysts. And regulatory documents shed further light on Pfizer's $4.9 billion takeover of Metsera, in which the New York pharma beat out two higher bidders for the promising obesity startup.  Finally, make sure to check out The 5 Most Powerful Women in Biopharma and BioSpace's inaugural 40 Under 40, highlighting 40 young leaders who have made an impact on the biopharma industry.  

A leading oncologist has warned that public patients are being denied ­powerful new cancer drugs which could keep them alive for longer or in some cases, cure them, while these same drugs are available to people who have health insurance. The oncologist in question, Dr. Michael McCarthy, a cancer specialist in Galway University Hospital, who has long campaigned to end the inequity, is now among a number of senior specialists who are supporting a letter to Health Minister Jennifer Carroll MacNeill proposing a co-funded early-access programme. Dr. Michael McCarthy, Consultant Oncologist at Galway University Hospital, joined Pat Kenny on the show.

AI science advances are FINALLY happening while OpenAI's Sam Altman & NVIDIA's Jensen Huang send billions back and forth. If $100 billion is a drop in the well, how much do they need? Plus, ChatGPT is causing divorces, new AI video models Kling 2.5 Turbo & Wan 2.5, Suno drops v5 & Gavin drops the fact that he's not *loving* Kevin's mustache. Oh & we're getting ready for the launch of AndThen, our new start up! Sign up now in the link below.   Get notified when AndThen launches: https://andthen.chat/ Come to our Discord to try our Secret Project: https://discord.gg/muD2TYgC8f Join our Patreon: https://www.patreon.com/AIForHumansShow AI For Humans Newsletter: https://aiforhumans.beehiiv.com/ Follow us for more on X @AIForHumansShow Join our TikTok @aiforhumansshow To book us for speaking, please visit our website: https://www.aiforhumans.show/   // Show Links // AI Psychedelics Are Here https://www.wired.com/story/a-startup-used-ai-to-make-a-psychedelic-without-the-trip/ Nvidia to Invest 100b In OpenAI (a lot of which will be spent on Nvidia chips) https://www.cnbc.com/2025/09/22/nvidia-openai-data-center.html “A Hundred Billion Is A Small Dent In It” Sam on CNBC https://x.com/sundeep/status/1970311723262656638 Sam Altman on “Abundant Intelligence” https://blog.samaltman.com/abundant-intelligence How will OpenAI pay for all this? Advertising. https://x.com/alexeheath/status/1970998934278676710 New models incoming that will be more that GPT-5 Pro  https://x.com/sama/status/19698 35407421374910 Meanwhile… ChatGPT is Causing Divorces https://futurism.com/chatgpt-marriages-divorces Suno v5 https://x.com/SunoMusic/status/1970583230807167300 Kevin's Terrible Mustache Https: //suno.com/s/j0b9Ukgd2CbtHVbu Kling 2.5 Is Pretty Good https://x.com/Kling_ai/status/1970439808901362155 Wan 2.5 With Audio https://blog.fal.ai/wan-2-5-preview-is-now-available-on-fal/ Wan Darth Vader https://x.com/fofrAI/status/1970877788384337977 Skild AI Robot Gets Legs Sawed Off & Learns To Walk Again https://x.com/SkildAI/status/1970940614234771579 Unitree's Anti-Gravity Mode https://x.com/UnitreeRobotics/status/1970039940022239491 If Stalin's Life Was A Video Game https://www.reddit.com/r/ChatGPT/comments/1npbwdr/if_they_made_a_video_game_about_the_life_of_stalin/ Carboarding: The Movie https://www.reddit.com/ r/ChatGPT/comments/1nmdipq/carboarding_the_movie/  

Date: Sept 16, 2025 Reference: Prada et al. Evaluation of the evidence on acetaminophen use and neurodevelopmental disorders using the Navigation Guide methodology. Environ Health. August 2025 Guest Skeptic: Dr. Andrew Martin is an emergency physician practicing in Jacksonville, Florida.  Case: A 27-year-old at 24 weeks' gestation presents to the emergency department (ED) with fever (38.6 °C), myalgias, and […] The post SGEM#485: I Want a New Drug – One Not Associated with Neurodevelopmental Disorders first appeared on The Skeptics Guide to Emergency Medicine.

Move over Sinaloa Cartel, there's a new kingpin in town

Is pornography hijacking your child's brain? In this essential episode of Parenting Great Kids with Dr. Meg Meeker, Dr. Meg sits down with Parker Hymas, Director of Public Outreach at Fight The New Drug, to expose the growing threat pornography poses to kids and teens in today's digital-first world.

Born with NF1-PN, a rare genetic disorder, Austin Fields spent his childhood learning how to live in a body riddled with benign tumors. Though removal surgery is the main treatment for this painful condition, a new medication has recently been approved for adults with NF1-PN. Our experts explain what it's like to live with this condition and how this novel drug is enhancing patients' quality of life. Learn More: https://radiohealthjournal.org/the-new-drug-that-shrinks-tumors-for-patients-with-nf1-pn Learn more about your ad choices. Visit megaphone.fm/adchoices

Carfentanil is making it's way through the Valley. We talked to the SAC of the DEA this hour about it and how to protect your kids. 

On this week's Headlines edition of the podcast, we start by summing up the most relevant details from the massive budget bill recently passed by Congress and signed by President Trump. We also discuss The Imprint's recent reporting on youth who enter foster care due to their behavioral health needs, and not because of abuse or neglect, and describe the new policies in New Mexico around removal of newborns who test positive for certain drugs. Reading RoomWhite House Watchhttps://imprintnews.org/special-series/white-house-watchThe Trump Admin is Withholding over $6 Billion in Education Grants for Schoolshttps://www.npr.org/2025/07/01/nx-s1-5453457/trump-school-funding-grants Trump Freezes Grant Funding, Upending School Budgetshttps://edsource.org/2025/california-education-federal-funding-cuts-teachers-english-learners/735665When Minnesota ParentsGive Up Their Kids to Foster Care: An Imprint Look at a Nationwide Predicamenthttps://imprintnews.org/child-welfare-2/when-minnesota-parents-give-up-their-kids-to-foster-care-an-imprint-look-at-a-nationwide-predicament/261820Michigan Justice Seeks ‘No-fault' Pathway to State Aid for Parents Who Can't Manage Kids' Mental Health Needshttps://imprintnews.org/top-stories/michigan-justice-seeks-no-fault-pathway-to-state-aid-for-parents-who-cant-manage-kids-mental-health-needs/262500Texas Lawmakers Take On Little-Known Pathway Into Foster Care: Parents Seeking Mental Health Treatment for Their Childrenhttps://imprintnews.org/top-stories/texas-lawmakers-take-on-little-known-pathway-into-foster-care-parents-seeking-mental-health-treatment-for-their-children/259701New Mexico Governor Plans to Crack Down on Families with Babies Born Addictedhttps://www.santafenewmexican.com/news/legislature/governor-plans-to-crack-down-on-families-with-babies-born-addicted/article_755e8552-554c-49ed-864f-df14dd1abaf4.html

Under a new proposal, Washington state taxpayers would foot the bill for addicts to get hard drugs. Prepare for sweeping statewide reparations. Congresswoman introduces “housing not handcuffs” bill. Teachers' union trains members on how to obstruct ICE. Elon Musk threatens to derail midterms over Big Beautiful Bill.

On January 17, the Biden-Harris Administration added 15 new drugs, including Ozempic, to the list of drugs covered by the Medicare Drug Price Negotiation Program of the Inflation Reduction Act (IRA). Now there are a total of 25 drugs that are covered by the IRA’s requirement that the Department of Health and Human Services (HHS) pays only a “fair price” for selected drugs covered by Medicare Part D. The new prices are set to take effect on January 1, 2027. What implications does this have for patients and for drug research and development? Join the discussion on the 'fair price' mandate and its impact on pharmaceutical innovation. Featuring: Lisa Ouellette, Deane F. Johnson Professor of Law at Stanford Law School Dan Troy, Managing Director at the Berkeley Research Group Brad Watts, Senior Vice President at the Global Innovation Policy Center, U.S. Chamber of Commerce [Moderator] Adam Mossoff, Professor of Law at Antonin Scalia Law School, George Mason University

Welcome to the Summer 2025 "Best of Series," where we replay our most popular episodes of the year so far. Whether you are relistening or hearing them for the first time, we pray that you are blessed, encouraged, and challenged. So sit back and enjoy; we'll see you back in August for all-new episodes. Today's episode is part of one of our Pornography Series with Ted Shimer and Hunter House.

Discussing recent FDA approvals of penpulimab, avutometenib, defactinib, and telisotuzumab vedotin.

Some hugely profitable drugs are targeted under new price controls. Big Pharma has been spending millions to fight them tooth and nail.Order Sharyl's new bestselling book: “Follow the $cience.” Subscribe to my two podcasts: “The Sharyl Attkisson Podcast” and “Full Measure After Hours.” Leave a review, subscribe and share with your friends! Support independent journalism by visiting the new Sharyl Attkisson store.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

BLACKOUT COFFEE!! Try Morning Reaper! You can get 20% off your first order- Just head to http://blackoutcoffee.com/hotseat and use code "hotseat" at checkout! Get Healthy! https://makewellness.com/273028 Join the Audio Podcast! https://podcasts.apple.com/us/podcast/the-hotseat/id1792653414 All the Links! https://linktr.ee/Toddspears1776 MERCH!!! https://www.redpillthreads.com/hotseat